{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T11:42:48Z","timestamp":1788090168192,"version":"build-2803163510"},"reference-count":53,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background\/Objectives: Orlistat is a gastrointestinal lipase inhibitor used for weight management. Although its established safety profile is largely characterised by fat malabsorption-related gastrointestinal events, post-marketing reports suggest a broader spectrum of adverse events. Given the increasing intersection between obesity pharmacotherapy and the management of non-alcoholic fatty liver disease\/metabolic dysfunction-associated steatotic liver disease (NAFLD\/MASLD), this study evaluated gastrointestinal, hepatobiliary, pancreatic, and anorectal adverse-event reporting signals associated with orlistat in the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) and assessed concordance with regulatory prescribing information. Methods: Quarterly FAERS files from 2004 Q1 through 2026 Q1 were analysed; some retained reports had Initial FDA Received Date (FDA_DT) values dating back to 1999. Descriptive analyses included all orlistat-associated reports, whereas disproportionality analyses were restricted to primary-suspect reports. Sixty-five prespecified Medical Dictionary for Regulatory Activities (MedDRA) preferred terms (PTs) were screened. Reporting odds ratios (RORs), 95% confidence intervals (CIs), and proportional reporting ratios (PRRs) were calculated. A signal was defined as ROR &gt; 2.0, lower bound of the 95% CI &gt; 1.0, and n \u2265 3. Two-sided p values calculated using Fisher\u2019s exact test on the corresponding 2 \u00d7 2 contingency tables were adjusted using the Benjamini\u2013Hochberg false discovery rate procedure to address multiple testing. Signal-positive PTs were cross-referenced with prescribing information from three jurisdictions. Results: Overall, 30,454 deduplicated orlistat-associated reports were identified, including 16,684 primary-suspect reports. Thirty-eight of the 65 prespecified MedDRA PTs met the signal criteria, and all remained statistically significant after Benjamini\u2013Hochberg false discovery rate correction (q &lt; 0.05). The strongest signals were rectal discharge (ROR 1175.53; 95% CI 1093.44\u20131263.78) and steatorrhoea (ROR 1147.99; 95% CI 1058.12\u20131245.50); change in bowel habit also showed a high ROR (47.32; 95% CI 38.27\u201358.51). Unlabelled signal-positive PTs included constipation, faeces hard, cholecystitis, and irritable bowel syndrome; change in bowel habit showed jurisdiction-specific labelling discordance. Conclusions: Orlistat-associated FAERS signals included both expected fat-malabsorption-related events and additional gastrointestinal, hepatobiliary, pancreatic, and anorectal PTs, several of which were not explicitly represented in the evaluated regulatory labels. These findings reflect disproportionate reporting rather than incidence, absolute risk, or causality and require confirmation in independent clinical or epidemiological data sources. They do not, by themselves, support regulatory labelling changes.<\/jats:p>","DOI":"10.3390\/ph19091325","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T08:03:41Z","timestamp":1787558621000},"page":"1325","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Orlistat-Associated Gastrointestinal, Hepatobiliary, Pancreatic, and Anorectal Safety Signals: A FAERS Disproportionality and Regulatory Label Concordance Study"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2738-625X","authenticated-orcid":false,"given":"Deniz","family":"\u00d6\u011f\u00fctmen Ko\u00e7","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, University of Health Sciences, Gaziosmanpa\u015fa Training and Research Hospital, Istanbul 34255, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8804-2501","authenticated-orcid":false,"given":"\u0130brahim","family":"Sarbay","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, University of Health Sciences, Gaziosmanpa\u015fa Training and Research Hospital, Istanbul 34255, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3183-3438","authenticated-orcid":false,"given":"Melike","family":"Mercan Ba\u015fp\u0131nar","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, University of Health Sciences, Gaziosmanpa\u015fa Training and Research Hospital, Istanbul 34255, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6622-7607","authenticated-orcid":false,"given":"L\u00fctfi","family":"Mangal","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Harran University, Urfa 63300, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6767-9092","authenticated-orcid":false,"given":"Burcu Eda","family":"Arda","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Toxicology, Faculty of Pharmacy, University of Health Sciences, Istanbul 34668, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6482-3143","authenticated-orcid":false,"given":"Hande","family":"Sipahi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Toxicology, Faculty of Pharmacy, University of Health Sciences, Istanbul 34668, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1592\/phco.20.4.270.34882","article-title":"Orlistat, a new lipase inhibitor for the management of obesity","volume":"20","author":"Heck","year":"2000","journal-title":"Pharmacotherapy"},{"key":"ref_2","unstructured":"World Health Organization (2024). Obesity and Overweight, World Health Organization. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s40264-014-0210-7","article-title":"Benefit-risk assessment of orlistat in the treatment of obesity","volume":"37","author":"Sumithran","year":"2014","journal-title":"Drug Saf."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1038\/s41591-025-03978-z","article-title":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","volume":"31","author":"McGowan","year":"2025","journal-title":"Nat. Med."},{"key":"ref_5","unstructured":"U.S. Food and Drug Administration (2026, June 26). FDA Approves Treatment for Serious Liver Disease Known as MASH, Available online: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-serious-liver-disease-known-mash."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/08998280.2024.2335829","article-title":"Efficacy of orlistat in obese patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Mahmoud","year":"2024","journal-title":"Proc. Bayl. Univ. Med. Cent."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.14744\/hf.2024.2024.0047","article-title":"Efficacy of orlistat for the treatment of metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis","volume":"6","author":"Ayati","year":"2025","journal-title":"Hepatol. Forum"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"100822","DOI":"10.1016\/j.curtheres.2026.100822","article-title":"Efficacy of orlistat on cardiometabolic indices in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): A GRADE-assessed systematic review and meta-analysis of RCTs","volume":"104","author":"Karimi","year":"2026","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2022.08.045","article-title":"AGA clinical practice guideline on pharmacological interventions for adults with obesity","volume":"163","author":"Grunvald","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Li, W., Liu, C., Zhang, Z., Cai, Z., Lv, T., Zhang, R., Zuo, Y., and Chen, S. (2024). Exploring the top 30 drugs associated with drug-induced constipation based on the FDA adverse event reporting system. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1443555"},{"key":"ref_11","unstructured":"U.S. Food and Drug Administration (2026, June 26). Xenical (Orlistat) Capsules, for Oral Use: Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/020766s038lbl.pdf."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e34837","DOI":"10.1016\/j.heliyon.2024.e34837","article-title":"Pharmacovigilance analysis of orlistat adverse events based on the FDA adverse event reporting system (FAERS) database","volume":"10","author":"Zhu","year":"2024","journal-title":"Heliyon"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_15","unstructured":"U.S. Food and Drug Administration (2026, June 26). FDA Adverse Event Monitoring System (AEMS) Public Dashboard and Data Limitations, Available online: https:\/\/www.fda.gov\/drugs\/fda-adverse-event-monitoring-system-aems\/fda-adverse-event-monitoring-system-aems-public-dashboard."},{"key":"ref_16","unstructured":"U.S. Food and Drug Administration (2026, June 26). Alli (Orlistat 60 mg Capsules): Over-the-Counter Label, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/021887lbl.pdf."},{"key":"ref_17","unstructured":"U.S. Food and Drug Administration (2026, June 26). Xenical (Orlistat) NDA 020766\/S-028 Supplement Approval Letter: Labeling Changes Regarding Severe Liver Injury, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2010\/020766s028ltr.pdf."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s40264-014-0225-0","article-title":"Stimulated reporting: The impact of U.S. Food and Drug Administration-issued alerts on the Adverse Event Reporting System (FAERS)","volume":"37","author":"Hoffman","year":"2014","journal-title":"Drug Saf."},{"key":"ref_19","unstructured":"European Medicines Agency (2022). Xenical: EPAR Product Information, European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xenical-epar-product-information_en.pdf."},{"key":"ref_20","unstructured":"Turkish Medicines and Medical Devices Agency (T\u0130TCK) (2026, June 26). Xenical 120 mg Sert Kaps\u00fcl: K\u0131sa \u00dcr\u00fcn Bilgisi [Turkish Prescribing Information], Available online: https:\/\/www.titck.gov.tr\/kubkt."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1526-4637.2005.00053.x","article-title":"Treatment of intractable constipation with orlistat: A report of three cases","volume":"6","author":"Guarino","year":"2005","journal-title":"Pain Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/apt.13555","article-title":"Letter: Orlistat as a potential treatment for chronic idiopathic constipation","volume":"43","author":"Iqbal","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/YIC.0b013e32835b08d2","article-title":"In a randomized placebo-controlled add-on study orlistat significantly reduced clozapine-induced constipation","volume":"28","author":"Chukhin","year":"2013","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_24","first-page":"150","article-title":"The impact of orlistat on diabetic patients experiencing overweight and constipation: A randomized clinical trial","volume":"17","author":"Zabihi","year":"2025","journal-title":"Iran. J. Diabetes Obes."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1345\/aph.1A452","article-title":"Constipation, polyuria, polydipsia, and edema associated with orlistat","volume":"36","author":"Packard","year":"2002","journal-title":"Ann. Pharmacother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/apt.17782","article-title":"Systematic review and meta-analysis: Foods, drinks and diets and their effect on chronic constipation in adults","volume":"59","author":"Katsirma","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/S1542-3565(05)00696-8","article-title":"The association of gastrointestinal symptoms with weight, diet, and exercise in weight-loss program participants","volume":"3","author":"Levy","year":"2005","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.7888\/juoeh.41.145","article-title":"Relationship between constipation and medication","volume":"41","author":"Ueki","year":"2019","journal-title":"J. UOEH"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Silveira, E.A., Santos, A.S.E.A.C., Ribeiro, J.N., Noll, M., Rodrigues, A.P.S., and de Oliveira, C. (2021). Prevalence of constipation in adults with obesity class II and III and associated factors. BMC Gastroenterol., 21.","DOI":"10.1186\/s12876-021-01806-5"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1467-789X.2011.00969.x","article-title":"Gastrointestinal symptoms and obesity: A meta-analysis","volume":"13","author":"Eslick","year":"2012","journal-title":"Obes. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"532","DOI":"10.7326\/0003-4819-142-7-200504050-00012","article-title":"Meta-analysis: Pharmacologic treatment of obesity","volume":"142","author":"Li","year":"2005","journal-title":"Ann. Intern. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/sj.ijo.0803323","article-title":"Safety profile of orlistat: Results of a prescription-event monitoring study","volume":"30","author":"Acharya","year":"2006","journal-title":"Int. J. Obes."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/cob.12075","article-title":"Orlistat-induced fulminant hepatic failure","volume":"4","author":"Sall","year":"2014","journal-title":"Clin. Obes."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.cgh.2006.02.004","article-title":"A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease","volume":"4","author":"Kessler","year":"2006","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"172","DOI":"10.5009\/gnl.2012.6.2.172","article-title":"Epidemiology of gallbladder disease: Cholelithiasis and cancer","volume":"6","author":"Stinton","year":"2012","journal-title":"Gut Liver"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"29937","DOI":"10.1038\/srep29937","article-title":"The association between gallstones and metabolic syndrome in urban Han Chinese: A longitudinal cohort study","volume":"6","author":"Zhu","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Chang, Y., Noh, Y.-H., Suh, B.-S., Kim, Y., Sung, E., Jung, H.-S., Kim, C.-W., Kwon, M.-J., Yun, K.E., and Noh, J.-W. (2018). Bidirectional association between nonalcoholic fatty liver disease and gallstone disease: A cohort study. J. Clin. Med., 7.","DOI":"10.3390\/jcm7110458"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.3748\/wjg.v18.i14.1652","article-title":"A population-based cohort study of symptomatic gallstone disease in diabetic patients","volume":"18","author":"Liu","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/j.cgh.2019.04.038","article-title":"Risk factors for severe liver disease in patients with type 2 diabetes","volume":"17","author":"Eliasson","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s40264-023-01345-w","article-title":"Challenges and opportunities in accessing and analysing FAERS data: A call towards a collaborative approach","volume":"46","author":"Giunchi","year":"2023","journal-title":"Drug Saf."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1046\/j.1365-2036.2004.01812.x","article-title":"Lipase inhibition by orlistat: Effects on gall-bladder kinetics and cholecystokinin release in obesity","volume":"19","author":"Roolker","year":"2004","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.regpep.2006.11.016","article-title":"Orlistat reduces gallbladder emptying by inhibition of CCK release in response to a test meal","volume":"139","author":"Ellrichmann","year":"2007","journal-title":"Regul. Pept."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1475-2891-5-19","article-title":"36-year-old man presenting with pancreatitis and a history of recent commencement of orlistat: Case report","volume":"5","author":"Napier","year":"2006","journal-title":"Nutr. J."},{"key":"ref_44","first-page":"61","article-title":"Acute pancreatitis following orlistat therapy: Report of two cases","volume":"11","author":"Ahmad","year":"2010","journal-title":"JOP"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000430433","article-title":"An unexpected result of obesity treatment: Orlistat-related acute pancreatitis","volume":"9","author":"Kose","year":"2015","journal-title":"Case Rep. Gastroenterol."},{"key":"ref_46","unstructured":"MedDRA MSSO (MedDRA Introductory Guide, 2024). MedDRA Introductory Guide, Version 27.0."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: A systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf."},{"key":"ref_49","unstructured":"U.S. Food and Drug Administration (2026, June 26). FDA Adverse Event Monitoring System (AEMS): Latest Quarterly Data Files, Available online: https:\/\/www.fda.gov\/drugs\/fda-adverse-event-monitoring-system-aems\/fda-adverse-event-monitoring-system-aems-latest-quarterly-data-files."},{"key":"ref_50","unstructured":"U.S. Food and Drug Administration (2026, June 26). FDA Launches New Adverse Event Look-Up Tool, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-launches-new-adverse-event-look-tool."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"Bate","year":"2002","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: A practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc. Ser. B Stat. Methodol."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/9\/1325\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T08:05:29Z","timestamp":1787558729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/9\/1325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,22]]},"references-count":53,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ph19091325"],"URL":"https:\/\/doi.org\/10.3390\/ph19091325","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,22]]}}}